Immunotherapy has become an essential part of cancer treatment after showing great efficacy in\nvarious malignancies. However, its effectiveness in pancreatic ductal adenocarcinoma (PDAC), especially in\nresectable pancreatic cancer, has not been studied. The primary objective of this study is to compare the OS impact\nof immunotherapy between PDAC patients who receive neoadjuvant immunotherapy and patients who receive\nadjuvant immunotherapy. The secondary objective is to investigate the impact of neoadjuvant and adjuvant\nimmunotherapy in combination with chemotherapy and chemoradiation by performing subset analyses of these\ntwo groups.\nMethods: Patients diagnosed with PDAC between 2004 and 2016 were identified from the National Cancer\nDatabase (NCDB). Multivariable Cox proportional hazard analysis was performed to examine the effect of\nneoadjuvant and adjuvant immunotherapy in combination with chemotherapy and chemoradiation on the OS of\nthe patients. The multivariable analysis was adjusted for essential factors such as the age at diagnosis, sex, race,\neducation, income, place of living insurance status, hospital type, comorbidity score, and year of diagnosis....................
Loading....